Keyphrases
Epidermal Growth Factor Receptor
100%
Lung Cancer Cells
100%
Pro-gastrin-releasing Peptide (ProGRP)
100%
Gastrin-releasing Peptide Receptor (GRPr)
100%
Non-small Cell Lung Cancer Cells
66%
Gefitinib
50%
Epidermal Growth Factor Receptor Ligands
50%
Non-small Cell Lung Cancer (NSCLC)
33%
Neutralizing Antibodies
33%
Matrix Metalloproteinase Inhibitors
16%
Ligand-receptor Binding
16%
Cell Death
16%
Cancer Proliferation
16%
Additive Effect
16%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
16%
P44/42 MAPK
16%
Cytotoxic Effect
16%
Human Lung Cancer Cell Line
16%
MAPK Activation
16%
HB-EGF
16%
Cell Proliferation Inhibition
16%
Fast Activation
16%
ID50
16%
Gefitinib-resistant
16%
Ligand Release
16%
Cancer Inhibition
16%
C225
16%
Anti-EGFR
16%
Gastrin-releasing Peptide Receptor Antagonist
16%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Gastrin Releasing Peptide Receptor
100%
Epidermal Growth Factor Receptor
100%
Non Small Cell Lung Cancer
70%
Gastrin Releasing Peptide
60%
Gefitinib
40%
Neutralizing Antibody
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Heparin Binding Epidermal Growth Factor
10%
Receptor Antagonist
10%
Matrix Metalloproteinase
10%
Cetuximab
10%
Cytotoxicity
10%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Gastrin-Releasing Peptide Receptor
100%
Epidermal Growth Factor Receptor
100%
Gastrin-Releasing Peptide
54%
Gefitinib
36%
Mitogen-Activated Protein Kinase
36%
Neutralizing Antibody
18%
Cell Proliferation
9%
Receptor Antagonist
9%
Receptor Tyrosine Kinase Inhibitors
9%
ID50
9%
Cytotoxicity
9%
Cell Death
9%
Matrix Metalloproteinase
9%
Heparin-Binding EGF-like Growth Factor
9%
Cetuximab
9%